Legal & General Group PLC Gritstone Bio, Inc. Transaction History

Legal & General Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$1.28 - $2.85 $1,696 - $3,776	-1,325 Reduced 15.69%	7,118 $14,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $14,015 - $25,582	8,443 New	8,443 $16,000
Q2 2022 Aug 22, 2022	SELL	$1.77 - $4.34 $6,156 - $15,094	-3,478 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.76 - $13.71 $2,216 - $3,468	253 Added 7.84%	3,478 $45,000
Q2 2021 Aug 12, 2021	BUY	$8.13 - $10.2 $5,251 - $6,589	646 Added 25.05%	3,225 $29,000
Q1 2021 May 17, 2021	SELL	$4.07 - $27.11 $1,062 - $7,075	-261 Reduced 9.19%	2,579 $24,000
Q3 2020 Nov 13, 2020	SELL	$2.63 - $8.09 $3,074 - $9,457	-1,169 Reduced 29.16%	2,840 $8,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $8.17 $2,913 - $4,183	512 Added 14.64%	4,009 $27,000
Q1 2020 May 14, 2020	SELL	$5.47 - $11.3 $4,791 - $9,898	-876 Reduced 20.03%	3,497 $20,000
Q4 2019 Feb 13, 2020	BUY	$7.07 - $11.61 $1,534 - $2,519	217 Added 5.22%	4,373 $39,000
Q2 2019 Aug 14, 2019	BUY	$9.2 - $15.7 $28,391 - $48,450	3,086 Added 288.41%	4,156 $42,000
Q4 2018 Feb 15, 2019	BUY	$11.61 - $31.1 $12,422 - $33,277	1,070 New	1,070 $17,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.